Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3633772

N#Cc1ccc(-c2nnc(-c3cccnc3)o2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.59
CYP11B2 P19099 3/20 0.54
RAB9A P51151 5/20 0.52
LMNA P02545 1/20 0.52
CA2 P00918 2/20 0.50
KDM4E B2RXH2 3/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTGS2 P35354 2/20 0.47
HSD17B10 Q99714 3/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
EGFR P00533 1/20 0.46
CA1 P00915 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3633423 0.88 CHRNB2 (0.54) NPC1RAB9ALMNAKDM4EPTGS2
SCHEMBL1422898 0.87 CYP11B2 (0.70) NPC1CYP11B2RAB9ALMNACA2
Trifluoroacetic Acid SCHEMBL3631758 0.86 NPC1 (0.63) NPC1RAB9ACA2KDM4EKMT2A
Trifluoroacetic Acid SCHEMBL3625741 0.86 NPC1 (0.63) NPC1RAB9ACA2KDM4EKMT2A
Trifluoroacetic Acid SCHEMBL3631429 0.85 NPC1 (0.61) NPC1RAB9ALMNACA2KDM4E
Trifluoroacetic Acid SCHEMBL3625608 0.85 NPC1 (0.74) NPC1RAB9ALMNACA2KDM4E
Trifluoroacetic Acid SCHEMBL3634033 0.85 NPC1 (0.61) NPC1RAB9ACA2KDM4EKMT2A
Trifluoroacetic Acid SCHEMBL4921697 0.85 NPC1 (0.82) NPC1RAB9ACA2KDM4EKMT2A
Trifluoroacetic Acid SCHEMBL4927459 0.85 NPC1 (0.74) NPC1RAB9ACA2KDM4EKMT2A
Trifluoroacetic Acid SCHEMBL4928304 0.83 NPC1 (0.58) NPC1RAB9ACA2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101715449-A Heterocyclic compounds and their methods of use ABBOTT LAB 2010-05-26 CN disclosed
EP-2146985-A1 HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE Abbott Laboratories (US) 2010-01-27 EP disclosed
WO-2008127464-A1 HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE ABBOTT LABORATORIES (US) 2008-10-23 WO disclosed
US-20080255203-A1 HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE ABBOTT LABORATORIES (US) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255203-A1 HETEROCYCLIC COMPOUNDS AND THEIR METHODS OF USE CYP11B2, AADAC, CYP11B1 NPC1 473/4885CYP11B2 1/4885RAB9A 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.